Pleural Mesothelioma clinical trials

Explore recruiting pleural mesothelioma clinical trials.

Recruiting pleural mesothelioma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Pleural Mesothelioma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

IFCT-2402 LAG-MAPS A non-comparative phase IIR trial assessing fianlimab plus cemiplimab plus pemetrexed-platinum chemotherapy or cemiplimab plus pemetrexed-platinum chemotherapy for treatment-naive Pleural Mesothelioma (PM) patients

France

Therapeutic exploratory (Phase II) EU CTIS Study details

FAPI PET in Pleural Mesothelioma: The Diagnostic Accuracy and Clinical Value of FAPI PET at Diagnosis, Primary Staging, and the Feasibility of FAPI PET for Response Evaluation

Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

PEMbrolizumab Plus Lenvatinib In Second Line And Third Line Malignant Pleural MEsotheLiomA Patients: A Single Arm Phase II Study (PEMMELA).

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (MEDI5752) in Combination with Carboplatin plus Pemetrexed Versus Platinum plus Pemetrexed or Nivolumab plus Ipilimumab in Participants with Unresectable Pleural Mesothelioma (eVOLVE-Meso)

Norway, France, Germany, Belgium, Spain, Poland +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

IFCT-2403 BI-MAPS Assessment of ivonescimab as salvage treatment in relapsing pleural mesothelioma patients, previously treated by immunotherapy and standard chemotherapy

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Phase II study of pembrolizumab in combination with cisplatin or carboplatin and pemetrexed as induction chemo+immunotherapy in resectable epithelioid and biphasic pleural mesothelioma (CHIMERA study)

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Pleural Mesothelioma trials by city

Pleural Mesothelioma in Toronto Pleural Mesothelioma in Vancouver Pleural Mesothelioma in Montreal Pleural Mesothelioma in Calgary Pleural Mesothelioma in Edmonton Pleural Mesothelioma in Ottawa Pleural Mesothelioma in Winnipeg Pleural Mesothelioma in Quebec City Pleural Mesothelioma in Hamilton Pleural Mesothelioma in Kitchener Pleural Mesothelioma in London Pleural Mesothelioma in Halifax Pleural Mesothelioma in New York Pleural Mesothelioma in Los Angeles Pleural Mesothelioma in Chicago Pleural Mesothelioma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease